Ensure Safe Use of CIMZIA

UCB is driven by a patient-forward philosophy, centered around promoting safe, quality patient care.

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage a known or potential serious risks associated with a drug or biological product and is required by the Food and Drug Administration to ensure that the benefits of the drug or biological product outweigh the risks for certain medications, like TNF alpha blockers.

In order for UCB to provide a safety plan to ensure that CIMZIA® is prescribed and taken safely, UCB has worked with the FDA to determine an appropriate communication plan for both physicians and patients. The REMS program is designed to inform health care providers and patients about the potential risks with CIMZIA. To learn how to minimize this these risks, read the important safety information provided on this page, refer to the Medication Guide provided, and discuss it with your doctor.